Romvimza

Active Ingredient(s): Vimseltinib
FDA Approved: * February 14, 2025
Pharm Company: * DECIPHERA PHARMS
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Romvimza 14 mg Oral Capsule
NDC: 73207-302
Labeler:
Deciphera Pharmaceuticals, LLC
Romvimza 20 mg Oral Capsule
NDC: 73207-303
Labeler:
Deciphera Pharmaceuticals, LLC
Romvimza 30 mg Oral Capsule
NDC: 73207-304
Labeler:
Deciphera Pharmaceuticals, LLC